# A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-

> **NCT02623738** · PHASE2,PHASE3 · COMPLETED · sponsor: **Santen Pharmaceutical Co., Ltd.** · enrollment: 253 (actual)

## Conditions studied

- Primary Open Angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** Placebo ophthalmic solution
- **DRUG:** DE-117 ophthalmic solution low
- **DRUG:** DE-117 ophthalmic solution high
- **DRUG:** Latanoprost ophthalmic solution 0.005%

## Key facts

- **NCT ID:** NCT02623738
- **Lead sponsor:** Santen Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-06
- **Primary completion:** 2017-02-10
- **Final completion:** 2017-02-10
- **Target enrollment:** 253 (ACTUAL)
- **Last updated:** 2017-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02623738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02623738, "A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02623738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*